Evidence map›Paper›PMID 32103936›Full record

ReviewInternational journal of nanomedicine2020

Subcellular Performance of Nanoparticles in Cancer Therapy.

Chen-Guang Liu, Ya-Hui Han, Ranjith Kumar Kankala, Shi-Bin Wang, Ai-Zheng Chen

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Palmitoylation of death receptor p75Alzheimer's research & therapy · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Peptide-coated DNA nanostructures as a platform for control of lysosomal function in cells.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2024
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chen-Guang Liu *Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, People's Republic of China.
Ya-Hui Han *Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, People's Republic of China.
Ranjith Kumar KankalaInstitute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, People's Republic of China.ORCID 0000-0003-4081-9179
Shi-Bin WangInstitute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, People's Republic of China.
Ai-Zheng ChenInstitute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, People's Republic of China.ORCID 0000-0002-5840-3406

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such as diagnostics, sensing, imaging, and drug delivery. Despite their success in delivering therapeutic agents, several traditional nanocarriers often end up with deprived selectivity and undesired therapeutic outcome, which significantly limit their clinical applicability. Further advancements in terms of improved selectivity to exhibit desired therapeutic outcome toward ablating cancer cells have been predominantly made focusing on the precise entry of nanoparticles into tumor cells via targeting ligands, and subsequent delivery of therapeutic cargo in response to specific biological or external stimuli. However, there is enough room intracellularly, where diverse small-sized nanomaterials can accumulate and significantly exert potentially specific mechanisms of antitumor effects toward activation of precise cancer cell death pathways that can be explored. In this review, we aim to summarize the intracellular pathways of nanoparticles, highlighting the principles and state of their destructive effects in the subcellular structures as well as the current limitations of conventional therapeutic approaches. Next, we give an overview of subcellular performances and the fate of internalized nanoparticles under various organelle circumstances, particularly endosome or lysosome, mitochondria, nucleus, endoplasmic reticulum, and Golgi apparatus, by comprehensively emphasizing the unique mechanisms with a series of interesting reports. Moreover, intracellular transformation of the internalized nanoparticles, prominent outcome and potential affluence of these interdependent subcellular components in cancer therapy are emphasized. Finally, we conclude with perspectives with a focus on the contemporary challenges in their clinical applicability.

Indexed as

AnimalsAntineoplastic AgentsCell NucleusDrug Delivery SystemsEndoplasmic ReticulumEndosomesHumansLysosomesMitochondriaNanoparticlesNeoplasmsAntineoplastic Agentscancer therapyintracellular pathwaysnanocompositesorganelleproton sponge effect

Identifiers

PMID32103936
PMCPMC7008395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.